In our most recent episode of “Ask the Doc,” we sat down with Dr. Anne Stevens, an esteemed member of the Cure JM Medical Advisory Board, to shed light on the various forms of CAR cell therapies that are making life-changing impacts in autoimmune diseases.
Dr. Stevens is fusing her decades of experience in the clinic with clinical trial prowess to bring hope to JM patients through revolutionary new treatment developments.
With CAR-T’s continued momentum in autoimmune disease research, there are now emerging therapies, including CAR-NK, that could lead to a more streamlined process with lessened side effects for patients.
Watch and learn as Dr. Stevens breaks down what CAR therapies are, the differences in CAR cell therapy approaches, and who the ideal autoimmune patients are that may benefit from this cutting-edge research.
More Information About the CAR Therapy Clinical Trials
CALiPSO-1 Clinical Trial Evaluating CAR-NK Cell Therapy (CAR-NK)
A phase 1 clinical trial testing CNTY-101, a treatment using CAR-NK (natural killer) cells to target harmful immune cells.
Review the CALiPSO-1 Clinical Trial Patient Sheet by clicking aquí.
Contact Info:
Email: trial_response_century@centurytx.com
¿Quién puede optar?
You may qualify if:
- You are 17 years of age or older
- You have a confirmed diagnosis of DM, PM, JDM, or JPM
- Your condition is considered refractory (not responding to traditional treatment)
- Learn more aquí
A study physician will determine final eligibility.
Where Is the Study Taking Place?
Currently Enrolling Sites:
- Los Angeles, CA (USC)
- Chicago, IL (Lurie Children’s Hospital)
- Houston, TX (Texas Children’s Hospital)
- Salt Lake City, UT (Primary Children’s Hospital)
Coming Soon:
- Sacramento, CA (UC Davis)
- View all study locations aquí
What is CNTY-101?
CNTY-101 is a CAR-NK cell product designed to target CD19, a marker on harmful B cells involved in autoimmune activity.
Interested in Learning More?
Download the CALiPSO-1 Study Flyer
Learn more about the trial aquí.
- All participants Trial will receive CAR-NK cell therapy — there is no placebo group in this study
Information on Current CAR-T Clinical Trial
RESET-Myositis Trial: CAR-T Cell Therapy (CABA-201)
Contact Info:
- Email: clinicaltrials@cabalettabio.com
- Phone: +1 (267) 759-3100
A phase 1/ 2 clinical trial, investigating a treatment that uses your own T cells to treat myositis
Who Can Participate:
- Children ages 6+ and adults with active myositis (JDM, JPM, or adult forms)
- Must have active disease
- Learn more aquí
A study physician will determine final eligibility.
How It Works:
- T cells are extracted from the patient, reengineered into CAR T cells, and returned to the patient to target harmful immune cells that may be causing disease
- All participants in the RESET-Myositis Trial will receive CAR-T cell therapy— there is no placebo group in this study
Where:
The trial is enrolling at multiple locations across the U.S., including:
Sites enrolling pediatric patients age 6-26*
- Chicago, IL (University of Chicago & Northwestern)
- San Francisco, CA (UCSF)
- Philadelphia, PA (CHOP) – coming soon!
- More locations listed aquí
Sites enrolling age 18+
- Orange County, CA (UC Irvine)
- Jacksonville, FL (Mayo Clinic)
- Nashville, TN (Vanderbilt)
- Houston, TX (Houston Methodist & MD Anderson)
- Kansas City, MO (UMKC)
- Rochester, MN (Mayo Clinic)
- Portland, OR (OHSU)
- Atlanta, GA (Emory)
- United Kingdom: London, Manchester, Salford
- More locations listed aquí
*Each children’s hospital may have slightly different maximum age guidelines, please contact clinicaltrials@cabalettabio.com to learn more
Travel:
- Travel to one of the sites may be covered, please contact to learn more
Want to learn more?
Talk to your doctor or email the study team at clinicaltrials@cabalettabio.com
